15 results on '"Allison, James P."'
Search Results
2. Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength
- Author
-
Egen, Jackson G. and Allison, James P.
- Subjects
- *
T cells , *CELL proliferation - Abstract
CD28 and CTLA-4 engagement with B7 expressed by APCs generates critical regulatory signals for T cell activation. CD28 is expressed on the T cell surface and enhances T cell expansion, while CTLA-4 localizes primarily to an intracellular compartment and inhibits T cell proliferation. We demonstrate that CTLA-4 has several unique trafficking properties that may regulate its ability to attenuate a T cell response. Importantly, accumulation of CTLA-4 at the immunological synapse is proportional to the strength of the TCR signal, suggesting that cells receiving stronger stimuli are more susceptible to CTLA-4-mediated inhibition. This may represent a novel feedback control mechanism in which a stimulatory signal regulates the recruitment of an inhibitory receptor to a functionally relevant site on the cell surface. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
3. Immune checkpoint therapy—current perspectives and future directions.
- Author
-
Sharma, Padmanee, Goswami, Sangeeta, Raychaudhuri, Deblina, Siddiqui, Bilal A., Singh, Pratishtha, Nagarajan, Ashwat, Liu, Jielin, Subudhi, Sumit K., Poon, Candice, Gant, Kristal L., Herbrich, Shelley M., Anandhan, Swetha, Islam, Shajedul, Amit, Moran, Anandappa, Gayathri, and Allison, James P.
- Subjects
- *
IMMUNE checkpoint proteins , *CANCER prognosis , *PATIENT selection , *DRUG side effects , *SYNTHETIC biology - Abstract
Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer patients and conferred durable clinical benefits, including cure in a subset of patients. Varying response rates across tumor types and the need for predictive biomarkers to optimize patient selection to maximize efficacy and minimize toxicities prompted efforts to unravel immune and non-immune factors regulating the responses to ICT. This review highlights the biology of anti-tumor immunity underlying response and resistance to ICT, discusses efforts to address the current challenges with ICT, and outlines strategies to guide the development of subsequent clinical trials and combinatorial efforts with ICT. Immune checkpoint therapy provides clinical benefits to many patients across different tumor types. Sharma, Goswami, and colleagues review the mechanisms of and clinical advances in immune checkpoint therapy and outline the challenges and approaches to broaden the clinical utility of immune checkpoint therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
- Author
-
Donkor, Moses K., Sarkar, Abira, Savage, Peter A., Franklin, Ruth A., Johnson, Linda K., Jungbluth, Achim A., Allison, James P., and Li, Ming O.
- Subjects
- *
PROSTATE cancer , *T cells , *CYTOKINES , *TRANSFORMING growth factors , *IMMUNOSUPPRESSION , *IMMUNE system , *CELLULAR signal transduction , *METASTASIS - Abstract
Summary: Tolerance induction in T cells takes place in most tumors and is thought to account for tumor evasion from immune eradication. Production of the cytokine TGF-β is implicated in immunosuppression, but the cellular mechanism by which TGF-β induces T cell dysfunction remains unclear. With a transgenic model of prostate cancer, we showed that tumor development was not suppressed by the adaptive immune system, which was associated with heightened TGF-β signaling in T cells from the tumor-draining lymph nodes. Blockade of TGF-β signaling in T cells enhanced tumor antigen-specific T cell responses and inhibited tumor development. Surprisingly, T cell- but not Treg cell-specific ablation of TGF-β1 was sufficient to augment T cell cytotoxic activity and blocked tumor growth and metastases. These findings reveal that T cell production of TGF-β1 is an essential requirement for tumors to evade immunosurveillance independent of TGF-β produced by tumors. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
5. T Cell Immunoglobulin Mucin-3 Crystal Structure Reveals a Galectin-9-Independent Ligand-Binding Surface
- Author
-
Cao, Erhu, Zang, Xingxing, Ramagopal, Udupi A., Mukhopadhaya, Arunika, Fedorov, Alexander, Fedorov, Elena, Zencheck, Wendy D., Lary, Jeffrey W., Cole, James L., Deng, Haiteng, Xiao, Hui, DiLorenzo, Teresa P., Allison, James P., Nathenson, Stanley G., and Almo, Steven C.
- Subjects
- *
T cells , *AUTOIMMUNE diseases , *IMMUNOGLOBULINS , *PHYSICAL biochemistry - Abstract
Summary: The T cell immunoglobulin mucin (Tim) family of receptors regulates effector CD4+ T cell functions and is implicated in autoimmune and allergic diseases. Tim-3 induces immunological tolerance, and engagement of the Tim-3 immunoglobulin variable (IgV) domain by galectin-9 is important for appropriate termination of T helper 1-immune responses. The 2 Å crystal structure of the Tim-3 IgV domain demonstrated that four cysteines, which are invariant within the Tim family, form two noncanonical disulfide bonds, resulting in a surface not present in other immunoglobulin superfamily members. Biochemical and biophysical studies demonstrated that this unique structural feature mediates a previously unidentified galectin-9-independent binding process and suggested that this structural feature is conserved within the entire Tim family. The current work provided a graphic example of the relationship between sequence, structure, and function and suggested that the interplay between multiple Tim-3-binding activities contributes to the regulated assembly of signaling complexes required for effective Th1-mediated immunity. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
6. B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse
- Author
-
Pentcheva-Hoang, Tsvetelina, Egen, Jackson G., Wojnoonski, Kathleen, and Allison, James P.
- Subjects
- *
SYNAPSES , *NEURAL transmission , *IMMUNOLOGY , *MOLECULES - Abstract
The reported affinity differences between CD28 and CTLA-4 binding to B7-1 and B7-2 may serve to selectively regulate CD28 and CTLA-4 function by differentially recruiting and/or stabilizing these molecules at the immunological synapse. Here we show that ligand binding is important for the accumulation of both CD28 and CTLA-4 at the synapse. While CD28 is recruited to the synapse in the absence of B7-1 and B7-2 binding, it is not effectively stabilized there, as its localization can be disrupted by CTLA-4. In the case of CTLA-4, ligand binding is critical for its concentration at the synapse. We also demonstrate that the affinity and avidity differences in ligand binding translate into selective recruitment of CD28 or CTLA-4 to the immunological synapse—B7-1 is the major ligand mediating CTLA-4 localization, while B7-2 is the main ligand for CD28 concentration at the synapse. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
7. Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States.
- Author
-
Wei, Spencer C., Sharma, Roshan, Anang, Nana-Ama A.S., Levine, Jacob H., Zhao, Yang, Mancuso, James J., Setty, Manu, Sharma, Padmanee, Wang, Jing, Pe'er, Dana, and Allison, James P.
- Subjects
- *
T cell differentiation , *T cells , *PROTEIN expression , *GEOGRAPHIC boundaries , *CYTOMETRY - Abstract
Co-stimulation regulates T cell activation, but it remains unclear whether co-stimulatory pathways also control T cell differentiation. We used mass cytometry to profile T cells generated in the genetic absence of the negative co-stimulatory molecules CTLA-4 and PD-1. Our data indicate that negative co-stimulation constrains the possible cell states that peripheral T cells can acquire. CTLA-4 imposes major boundaries on CD4 + T cell phenotypes, whereas PD-1 subtly limits CD8 + T cell phenotypes. By computationally reconstructing T cell differentiation paths, we identified protein expression changes that underlied the abnormal phenotypic expansion and pinpointed when lineage choice events occurred during differentiation. Similar alterations in T cell phenotypes were observed after anti-CTLA-4 and anti-PD-1 antibody blockade. These findings implicate negative co-stimulation as a key regulator and determinant of T cell differentiation and suggest that checkpoint blockade might work in part by altering the limits of T cell phenotypes. • Negative co-stimulation limits T cell differentiation outcomes • Archetypal analysis identifies phenotypic boundaries of cell states • CTLA-4 imposes major boundaries on CD4 + T cell phenotypes • PD-1 subtly restrains CD8+ T cell phenotypes Negative co-stimulation is a critical regulator of T cell activity. Wei et al. characterize T cells arising in CTLA-4- and PD-1-deficient mice via mass-cytometry and computational approaches. They show that these negative co-stimulatory molecules impose boundaries on T cell phenotypes during peripheral differentiation, suggesting that checkpoint blockade might work in part by altering the limits of T cell phenotypes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
- Author
-
Wei, Spencer C., Levine, Jacob H., Cogdill, Alexandria P., Zhao, Yang, Anang, Nana-Ama A.S., Andrews, Miles C., Sharma, Padmanee, Wang, Jing, Wargo, Jennifer A., Pe’er, Dana, and Allison, James P.
- Subjects
- *
CYTOTOXIC T lymphocyte-associated molecule-4 , *IMMUNE system , *CANCER cells , *LABORATORY mice , *CD4 antigen , *IMMUNE response , *CELLULAR immunity - Abstract
Summary Immune-checkpoint blockade is able to achieve durable responses in a subset of patients; however, we lack a satisfying comprehension of the underlying mechanisms of anti-CTLA-4- and anti-PD-1-induced tumor rejection. To address these issues, we utilized mass cytometry to comprehensively profile the effects of checkpoint blockade on tumor immune infiltrates in human melanoma and murine tumor models. These analyses reveal a spectrum of tumor-infiltrating T cell populations that are highly similar between tumor models and indicate that checkpoint blockade targets only specific subsets of tumor-infiltrating T cell populations. Anti-PD-1 predominantly induces the expansion of specific tumor-infiltrating exhausted-like CD8 T cell subsets. In contrast, anti-CTLA-4 induces the expansion of an ICOS + Th1-like CD4 effector population in addition to engaging specific subsets of exhausted-like CD8 T cells. Thus, our findings indicate that anti-CTLA-4 and anti-PD-1 checkpoint-blockade-induced immune responses are driven by distinct cellular mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
- Author
-
Gao, Jianjun, Shi, Lewis Zhichang, Zhao, Hao, Chen, Jianfeng, Xiong, Liangwen, He, Qiuming, Chen, Tenghui, Roszik, Jason, Bernatchez, Chantale, Woodman, Scott E., Chen, Pei-Ling, Hwu, Patrick, Allison, James P., Futreal, Andrew, Wargo, Jennifer A., and Sharma, Padmanee
- Subjects
- *
MELANOMA treatment , *INTERFERON gamma , *IMMUNOREGULATION , *T cells , *INTERFERON receptors , *IPILIMUMAB , *THERAPEUTICS - Abstract
Summary Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including production of IFN-γ, which is a critical cytokine for host immune responses. However, the role of IFN-γ signaling in tumor cells in the setting of anti-CTLA-4 therapy remains unknown. Here, we demonstrate that patients identified as non-responders to anti-CTLA-4 (ipilimumab) have tumors with genomic defects in IFN-γ pathway genes. Furthermore, mice bearing melanoma tumors with knockdown of IFN-γ receptor 1 (IFNGR1) have impaired tumor rejection upon anti-CTLA-4 therapy. These data highlight that loss of the IFN-γ signaling pathway is associated with primary resistance to anti-CTLA-4 therapy. Our findings demonstrate the importance of tumor genomic data, especially IFN-γ related genes, as prognostic information for patients selected to receive treatment with immune checkpoint therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.
- Author
-
Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks JK, Awiwi M, Elsayes K, Soto LS, Melendez BD, Davies MA, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison JP, Hwu P, Ekmekcioglu S, and Diab A
- Subjects
- Animals, Humans, Immunologic Factors therapeutic use, Immunotherapy, Interleukin-6, Mice, Myeloid Cells, Colitis chemically induced, Neoplasms drug therapy
- Abstract
Immune checkpoint blockade (ICB) therapy frequently induces immune-related adverse events. To elucidate the underlying immunobiology, we performed a deep immune analysis of intestinal, colitis, and tumor tissue from ICB-treated patients with parallel studies in preclinical models. Expression of interleukin-6 (IL-6), neutrophil, and chemotactic markers was higher in colitis than in normal intestinal tissue; T helper 17 (Th17) cells were more prevalent in immune-related enterocolitis (irEC) than T helper 1 (Th1). Anti-cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4) induced stronger Th17 memory in colitis than anti-program death 1 (anti-PD-1). In murine models, IL-6 blockade associated with improved tumor control and a higher density of CD4
+ /CD8+ effector T cells, with reduced Th17, macrophages, and myeloid cells. In an experimental autoimmune encephalomyelitis (EAE) model with tumors, combined IL-6 blockade and ICB enhanced tumor rejection while simultaneously mitigating EAE symptoms versus ICB alone. IL-6 blockade with ICB could de-couple autoimmunity from antitumor immunity., Competing Interests: Declaration of interests A.D. received Institution Research funds: Bristol Myers and Squibb, Merck, Pfizer, Nektar Therapeutics, Idera Pharmaceuticals, Apexigen and advisory board fees: Bristol Myers and Squibb, Nektar Therapeutics, Idera Pharmaceuticals, Iovance Therapeutics, Apexigen. M.A.D. has been a consultant to Roche/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, Iovance, and ABM Therapeutics, and he has been the PI of research grants to MD Anderson by Roche/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, Oncothyreon, and ABM Therapeutics., (Copyright © 2022 Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
11. Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival.
- Author
-
Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, and Kalluri R
- Published
- 2015
- Full Text
- View/download PDF
12. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.
- Author
-
Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, and Wolchok JD
- Subjects
- Animals, Cell Movement, Cells, Cultured, Humans, Immunosuppressive Agents pharmacology, Indoleamine-Pyrrole 2,3,-Dioxygenase pharmacology, Mice, Myeloid Cells drug effects, Myeloid Cells physiology, Indoleamine-Pyrrole 2,3,-Dioxygenase immunology, Myeloid Cells immunology, Neoplasms immunology, T-Lymphocytes, Regulatory immunology
- Abstract
Indoleamine 2,3-dioxygenase (IDO) has been described as a major mechanism of immunosuppression in tumors, though the mechanisms of this are poorly understood. Here, we find that expression of IDO by tumor cells results in aggressive tumor growth and resistance to T-cell-targeting immunotherapies. We demonstrate that IDO orchestrates local and systemic immunosuppressive effects through recruitment and activation of myeloid-derived suppressor cells (MDSCs), through a mechanism dependent on regulatory T cells (Tregs). Supporting these findings, we find that IDO expression in human melanoma tumors is strongly associated with MDSC infiltration. Treatment with a selective IDO inhibitor in vivo reversed tumor-associated immunosuppression by decreasing numbers of tumor-infiltrating MDSCs and Tregs and abolishing their suppressive function. These findings establish an important link between IDO and multiple immunosuppressive mechanisms active in the tumor microenvironment, providing a strong rationale for therapeutic targeting of IDO as one of the central regulators of immune suppression., (Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
13. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.
- Author
-
Sharma P and Allison JP
- Subjects
- Animals, Humans, Mutation, Neoplasms genetics, Neoplasms immunology, Precision Medicine, Signal Transduction drug effects, T-Lymphocytes immunology, Drug Delivery Systems, Immunotherapy, Neoplasms therapy
- Abstract
Research in two fronts has enabled the development of therapies that provide significant benefit to cancer patients. One area stems from a detailed knowledge of mutations that activate or inactivate signaling pathways that drive cancer development. This work triggered the development of targeted therapies that lead to clinical responses in the majority of patients bearing the targeted mutation, although responses are often of limited duration. In the second front are the advances in molecular immunology that unveiled the complexity of the mechanisms regulating cellular immune responses. These developments led to the successful targeting of immune checkpoints to unleash anti-tumor T cell responses, resulting in durable long-lasting responses but only in a fraction of patients. In this Review, we discuss the evolution of research in these two areas and propose that intercrossing them and increasing funding to guide research of combination of agents represent a path forward for the development of curative therapies for the majority of cancer patients., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
14. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.
- Author
-
Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, and Kalluri R
- Subjects
- Animals, Carcinoma, Pancreatic Ductal immunology, Disease Models, Animal, Fibroblasts immunology, Fibrosis immunology, Humans, Immune Tolerance, Mice, Mice, Transgenic, Pancreatic Neoplasms immunology, Survival Analysis, Carcinoma, Pancreatic Ductal pathology, Fibroblasts pathology, Fibrosis pathology, Pancreatic Neoplasms pathology
- Abstract
Pancreatic ductal adenocarcinoma (PDAC) is associated with marked fibrosis and stromal myofibroblasts, but their functional contribution remains unknown. Transgenic mice with the ability to delete αSMA(+) myofibroblasts in pancreatic cancer were generated. Depletion starting at either noninvasive precursor (pancreatic intraepithelial neoplasia) or the PDAC stage led to invasive, undifferentiated tumors with enhanced hypoxia, epithelial-to-mesenchymal transition, and cancer stem cells, with diminished animal survival. In PDAC patients, fewer myofibroblasts in their tumors also correlated with reduced survival. Suppressed immune surveillance with increased CD4(+)Foxp3(+) Tregs was observed in myofibroblast-depleted mouse tumors. Although myofibroblast-depleted tumors did not respond to gemcitabine, anti-CTLA4 immunotherapy reversed disease acceleration and prolonged animal survival. This study underscores the need for caution in targeting carcinoma-associated fibroblasts in PDAC., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
15. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative.
- Author
-
Peggs KS, Segal NH, and Allison JP
- Subjects
- Antibodies, Monoclonal immunology, Apoptosis, Genomic Instability, Humans, Models, Immunological, Neoplasms drug therapy, Neoplasms immunology, T-Lymphocytes immunology, Immunotherapy methods, Neoplasms therapy
- Abstract
In this Commentary we aim to provide an overview of some specific examples of cancer therapeutics, including targeted approaches using monoclonal antibodies and kinase inhibitors, as well as highlight novel approaches for enhancing immunological responses against tumors. We point out that a fundamental property of the cancer cell, genomic instability, confounds the targeted therapies that aim to induce cell death directly while simultaneously enhancing the potential for immunological attack by creating a large number of neoantigens. We argue for combinatorial strategies with agents that target tumor cells to release these antigens together with innovative therapies that enhance immunological responses by interfering with inhibitory checkpoints.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.